NIH R01 · 2025
The Role and Therapeutic Targeting of GPR56 in Colorectal Cancer
ABSTRACT: Colorectal Cancer (CRC) remains the second leading cause of cancer-related deaths as current treatments for advanced disease have been limited by low response rates and adverse side-effects. Failure of treatment is attributed to tumor heterogeneity and the presence of cancer stem-like cells (CSCs). Plasticity of CSCs has been shown to drive therapy resistance and metastasis. Identifying novel targets involved in plasticity and disease progression is important for the development of more effective therapies. GPR56, a member of the adhesion G protein-coupled receptor family, is highly expressed in a large fraction of CRC and is associated with poor prognosis. We showed GPR56…
From the public funding record at NIH RePORTER. Describes the funded project, not the reviews below.